Labviva Secures $25 Million to Enhance AI-Driven Life Sciences Procurement Platform
Labviva Inc., a Massachusetts-based startup revolutionizing the life sciences procurement process with its AI-powered platform, has successfully raised $25 million in a Series B funding round. The investment aims to fuel the company’s expansion into international markets, accelerate product innovation, and bolster customer support and marketing efforts.

Labviva Inc., a Massachusetts-based startup revolutionizing the life sciences procurement process with its AI-powered platform, has successfully raised $25 million in a Series B funding round. The investment aims to fuel the company’s expansion into international markets, accelerate product innovation, and bolster customer support and marketing efforts.
Established in 2017, Labviva operates a digital marketplace that connects researchers with suppliers of reagents, chemicals, consumables, and instruments. By leveraging artificial intelligence, the platform enhances transparency in the life sciences supply chain—a system critical to the sourcing, manufacturing, and distribution of materials used in research, diagnostics, and healthcare.
Through its innovative approach, Labviva brings scientists, procurement teams, and suppliers together, streamlining purchasing and supply chain management processes. The platform covers approximately 90% of life science suppliers, granting users immediate access to a diverse network of sellers, including major suppliers and smaller, environmentally certified businesses. This comprehensive coverage enables customers to compare products and pricing efficiently, tailored to company-specific needs. The system is designed to reduce research and development costs, save time spent on manual product searches, and prevent inventory gaps.
The recent Series B round was led by 53 Stations, with participation from previous investors Biospring Partners LP, B Capital Group Management LP, and Glasswing Ventures. Jason Pritzker, co-founder and managing partner of 53 Stations, will join Labviva’s board of directors, further solidifying the company’s leadership team.
Commenting on the milestone, Labviva’s co-founder and CEO Siamak Baharloo stated, “We’ve been laser-focused on building close customer and supplier relationships and deploying solutions that drive instant, long-term results. This strategy paid off because today, we’ve reached an inflection point that positions Labviva for massive growth.”
The company’s AI-driven platform is particularly noted for its ability to automate procurement processes, offering detailed product insights and supply chain tracking. Such advancements are pivotal for laboratories seeking to optimize resource management and ensure uninterrupted research activities. The platform’s success reflects the increasing demand for smarter, data-driven solutions in life sciences procurement.
With the latest funding, Labviva has raised a total of $50.8 million to date, according to data from Tracxn, a venture capital intelligence platform. This financial backing positions the company to scale its operations globally, enhance its technological capabilities, and strengthen its market presence.
As the life sciences industry continues to evolve, the demand for streamlined procurement solutions like those offered by Labviva underscores the growing intersection of technology and research. This latest funding round highlights investor confidence in the company's potential to shape the future of life sciences procurement.